Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-214868 · 2 trials · 2 indications
The average number of urinary episodes (urination into the toilet) was recorded by a patient bladder diary during 3 consecutive days in the week prior to Baseline and Week 12. A negative change from Baseline indicated improvement (fewer urinary episodes).
Participants rated the severity of their daily pain in the previous 7 days using a 10 point scale where 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.
| Arm | Type | Description |
|---|---|---|
| AGN-214868 total dose 500 ng | EXPERIMENTAL | AGN-214868 injected into the bladder for total dose of 500 ng on Day 1. |
| AGN-214868 total dose 1000 ng | EXPERIMENTAL | AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1. |
| AGN-214868 total dose 2000 ng | EXPERIMENTAL | AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1. |
| AGN-214868 total dose 6000 ng | EXPERIMENTAL | AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1. |
| AGN-214868 total dose 18000 ng | EXPERIMENTAL | AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1. |
| AGN-214868 total dose 60000 ng | EXPERIMENTAL | AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1. |
| Placebo to AGN-214868 | PLACEBO_COMPARATOR | Placebo to AGN-214868 injected into the bladder on Day 1. |
| AGN-214868 3.25 μg | EXPERIMENTAL | AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment. |
| AGN-214868 16.25 μg | EXPERIMENTAL | AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment. |
| Placebo | PLACEBO_COMPARATOR | Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment. |
| Name | Type | Description |
|---|---|---|
| AGN-214868 | DRUG | AGN-214868 injected into the bladder. |
| AGN-214868 placebo | DRUG | AGN-214868 placebo injected into the bladder. |
| Placebo to AGN-214868 | DRUG | Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment. |
Inclusion Criteria: * If female, must be of nonreproductive potential * If male, must agree to use acceptable contraception * Symptoms of overactive bladder with urinary urgency incontinence * Inadequate response or limiting side effects with anticholinergics for the treatment of OAB Exclusion Cri...
AGN-214868 is an investigational small molecule being studied for postherpetic neuralgia and overactive bladder with urinary incontinence. It is in Phase 2 clinical development and is not approved by the FDA.
AGN-214868 is being developed by AbbVie Inc., traded on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 2 clinical trials.
AGN-214868 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one in postherpetic neuralgia and one in overactive bladder. The drug is investigational and not yet approved.
AGN-214868 has completed two Phase 2 trials. NCT01129531 studied the drug in 294 patients with postherpetic neuralgia in the US, Czechia, Germany, and Poland. NCT01157377 studied it in 160 patients with overactive bladder in the US, France, and the Netherlands.
AGN-214868 is the primary name for this investigational compound. No alternative names have been reported in clinical trial records. It is a small molecule being developed by AbbVie for pain and urological conditions.